Alterations in the Expression of Proprotein Convertase Genes in Human Esophagus Squamous Cell Carcinomas. [PDF]
Komissarov AA +8 more
europepmc +1 more source
Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]
Li Z +14 more
europepmc +1 more source
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipid Profile and Cardiovascular Events in High-Risk Diabetic Patients. [PDF]
Patra V +6 more
europepmc +1 more source
Pathogenic Deep Intronic PCSK1 Variant Causes Proprotein Convertase 1/3 Deficiency in a Family. [PDF]
Huber LM +6 more
europepmc +1 more source
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach. [PDF]
Zheng X +6 more
europepmc +1 more source
Comment on: PACE4 (PCSK6): another proprotein convertase linked to iron homeostasis?
Alessia Pagani +5 more
doaj +1 more source
A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model. [PDF]
Grignano MA +20 more
europepmc +1 more source
Dysregulation of FURIN and Other Proprotein Convertase Genes in the Progression from HPV Infection to Cancer. [PDF]
Izaguirre G, Zirou N, Meyers C.
europepmc +1 more source
<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]
Woźniak E +6 more
europepmc +1 more source
Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome. [PDF]
Pihtili Taş N +7 more
europepmc +1 more source

